Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 10, 2022
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
Mark Breidenbach Maintained (SYRS) at Buy with Decreased Target to $30 on, Aug 10th, 2022
Mark Breidenbach of Oppenheimer, Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Buy with Decreased Target from $90 to $30 on, Aug 10th, 2022.
Mark has made no other calls on SYRS in the last 4 months.
There are 2 other peers that have a rating on SYRS. Out of the 2 peers that are also analyzing SYRS, 0 agree with Mark's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mark
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Tuesday, July 12th, 2022
- Matt Cross of "Alliance Global Partners" Maintained at Strong Buy with Decreased Target to $100 on, Tuesday, May 17th, 2022
